Yale Clinical Trials providers

Click on their name to visit their faculty profile page:
Brinda Emu | Onyema Ogbuagu | Michael Kozal | Serena Spudich | Ritche Hao)

For information about Clinical Trials and Enrollment:

Laurie Andrews, RN, MPH | Office: 203-785-3557

Cindy Frank RN PhD | Office: 203 785-6939

Trials Active Enrolling

  • CytoDyn PRO 140 Monotherapy for the chronic suppression of CCR5-tropic HIV infection (PI-Ogbuagu)
  • Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332): NIAID/NHLBI (PI-Kozal)
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 (humanized monoclonal antibody to CCR5) in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects. (PI-Ogbuagu)
  • Protocol TMB-311 study – A Phase 3, Multicenter Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected with Multi-Drug Resistant (MDR) HIV-1. (PI- Emu)

Ongoing Trials – closed to enrollment

  • Comparison of Truvada vs Descovy for PrEP in HIV negative gay men or transgendered women. GS-US-412-2055 (PI-Ogbuagu)
  • Strategic Timing of AntiRetroviral Treatment (START) INSIGHT PROTOCOL: NIAID (PI- Friedland)
  • BMS AI438-047: A Multi-Arm Phase 3 Trial of BMS-663068 (Attachment Inhibitor) in Heavily Experienced HIV-1 Subjects with MDR HIV (PI- Kozal)
  • MERK-Edge: A Phase III Clinical Trial of MK-5172 + MK-8742 in Subjects with Chronic HCV GT1, GT4 and GT6 infection who are on Opiate Substitution Therapy. HIV+ or Negative (PI-Altice)

Ongoing Trials that will be completed in 2017

  • GS-US-366-1216: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) (PI- Kozal)
  • GS-US-366-1160: A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects. (PI- Kozal)